Anna Pia Enblad

Anna Pia Enblad

Auto-generated profile, based on publicly available information

Anna Pia Enblad

Uppsala University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Scandinavian Journal of Urology
Verified
Journal Article
Open access
AEAnna Pia Enblad
Anna Pia Enblad
OBOskar Bergengren
Oskar Bergengren
OAOve Andrén
Ove Andrén
ALAnders Larsson
Anders Larsson
KFKatja Fall
Katja Fall
ABAnna Bill-Axelson
Anna Bill-Axelson
Organized PSA testing for asymptomatic men aged 50–74 years will be implemented in Sweden to reduce opportunistic testing in groups who will not benefit. The aim of this study was to describe the o...

5 January 2024 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
PDF file
HGHenrik Gezelius
Henrik Gezelius
AEAnna Pia Enblad
Anna Pia Enblad
ALAnders Lundmark
Anders Lundmark
MÅMartin Åberg
Martin Åberg
KBKristin Blom
Kristin Blom
Jessica NordlundJessica Nordlund
Jessica Nordlund
Functional precision medicine (FPM) aims to optimize patient-specific drug selection based on the unique characteristics of their cancer cells. Recent advancements in high throughput ex vivo drug profiling have accelerated interest in FPM. Here, we present a proof-of-concept study for an integrated experimental system that incorporates ex vivo treatment response with a single-cell gene expression output enabling barcoding of several drug conditions in one single-cell sequencing experiment. We demonstrate this through a proof-of-concept investigation focusing on the glucocorticoid-resistant acute lymphoblastic leukemia (ALL) E/R+ Reh cell line. Three different single-cell transcriptome sequencing (scRNA-seq) approaches were evaluated, each exhibiting high cell recovery and accurate tagging of distinct drug conditions. Notably, our comprehensive analysis revealed variations in library complexity, sensitivity (gene detection), and differential gene expression detection across the methods. Despite these differences, we identified a substantial transcriptional response to fludarabine, a highly relevant drug for treating high-risk ALL, which was consistently recapitulated by all three methods. These findings highlight the potential of our integrated approach for studying drug responses at the single-cell level and emphasize the importance of method selection in scRNA-seq studies. Finally, our data encompassing 27 327 cells are freely available to extend to future scRNA-seq methodological comparisons.

10 August 2020 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
OBOskar Bergengren
Oskar Bergengren
AEAnna Pia Enblad
Anna Pia Enblad
HGHans Garmo
Hans Garmo
OBOla Bratt
Ola Bratt
LHLars Holmberg
Lars Holmberg
ABAnna Bill‐Axelson
Anna Bill‐Axelson
Objective: Long‐term information on lifestyle changes among prostate survivors is lacking. In this nationwide, population‐based study we investigated the prevalence of lifestyle changes, factors associated with lifestyle changes and associations between lifestyle changes and general quality of life.Methods: All men registered in the National Prostate Cancer Register of Sweden diagnosed in 2008 with low‐risk prostate cancer at age 70 years or younger were sent a questionnaire. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals for factors potentially associated with lifestyle change.Results: Out of 1288, 1720 men (75%) were responded. A total of 279 (22%) reported a positive lifestyle change regarding diet or exercise. Poor functional outcomes after treatment was associated with exercising less (OR 1.6, 95% CI 1.2‐2.1) and less interest in social activities and relationships (OR 1.8, 95% CI 1.5‐2.1). Men who exercised more (OR 7.9, 95% CI 4.4‐14) and men who had an increased interest in relationships and social activities (OR 5.2, 95% CI 2.1‐13) reported higher general quality of life.Conclusions: A considerable proportion of men reported making positive lifestyle changes after the prostate cancer diagnosis. The time after diagnosis may be a teachable moment that facilitates lifestyle interventions. Poor functional outcomes after treatment may reduce the willingness to engage in positive lifestyle change, which need be considered when supporting men after treatment. Men who made a positive lifestyle change, regardless of whether it was exercise or regarding relationships and social activities more often reported a high level of general quality of life.

27 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
OKOlga Krali
Olga Krali
YMYanara Marincevic-Zuniga
Yanara Marincevic-Zuniga
GAGustav Arvidsson
Gustav Arvidsson
AEAnna Pia Enblad
Anna Pia Enblad
ALAnders Lundmark
Anders Lundmark
Jessica NordlundJessica Nordlund
Jessica Nordlund
Genomic analyses have redefined the molecular subgrouping of pediatric acute lymphoblastic leukemia (ALL). Molecular subgroups guide risk-stratification and targeted therapies, but outcomes of recently identified subtypes are often unclear, owing to limited cases with comprehensive profiling and cross-protocol studies. We developed a machine learning tool (ALLIUM) for the molecular subclassification of ALL in retrospective cohorts as well as for up-front diagnostics. ALLIUM uses DNA methylation and gene expression data from 1131 Nordic ALL patients to predict 17 ALL subtypes with high accuracy. ALLIUM was used to revise and verify the molecular subtype of 280 cases with undefined/B-other molecular phenotype, resulting in a single revised subtype for 85.4% of these cases. Our study shows the power of combining DNA methylation and gene expression data for resolving ALL subtypes and provides the first comprehensive population-based retrospective cohort study of molecular subtype frequencies in the Nordic countries, identifying subgroups with differential survival outcomes.

1 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
HGHenrik Gezelius
Henrik Gezelius
AEAnna Pia Enblad
Anna Pia Enblad
ALAnders Lundmark
Anders Lundmark
MÅMartin Åberg
Martin Åberg
KBKristin Blom
Kristin Blom
Jessica NordlundJessica Nordlund
Jessica Nordlund
Functional precision medicine (FPM) aims to optimize patient-specific drug selection based on the unique characteristics of their cancer cells. Recent advancements in high throughput ex vivo drug profiling have accelerated interest in FPM. Here, we present a proof-of-concept study for an integrated experimental system that incorporates ex vivo treatment response with a single-cell gene expression output enabling barcoding of several drug conditions in one single-cell sequencing experiment. We demonstrate this through a proof-of-concept investigation focusing on the glucocorticoid-resistant acute lymphoblastic leukemia (ALL) E/R+ Reh cell line. Three different single-cell transcriptome sequencing (scRNA-seq) approaches were evaluated, each exhibiting high cell recovery and accurate tagging of distinct drug conditions. Notably, our comprehensive analysis revealed variations in library complexity, sensitivity (gene detection), and differential gene expression detection across the methods. Despite these differences, we identified a substantial transcriptional response to fludarabine, a highly relevant drug for treating high-risk ALL, which was consistently recapitulated by all three methods. These findings highlight the potential of our integrated approach for studying drug responses at the single-cell level and emphasize the importance of method selection in scRNA-seq studies. Finally, our data encompassing 27,327 cells are freely available to extend to future scRNA-seq methodological comparisons.

11 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMaria Ascencion Globisch
Maria Ascencion Globisch
HGHenrik Gezelius
Henrik Gezelius
AEAnna Pia Enblad
Anna Pia Enblad
ALAnders Lundmark
Anders Lundmark
MWMariya A Lysenkova Wiklander
Mariya A Lysenkova Wiklander
Jessica NordlundJessica Nordlund
Jessica Nordlund
Recent advancements in spatial biology have revolutionized our understanding of the organization and functional dynamics of cells and tissues. In this study, we applied Molecular Pixelation (MPX), a single-cell spatial proteomics assay, to investigate the modulation of the cell surface proteome in an in vitro drug screening model using the ETV6::RUNX1 acute lymphoblastic leukemia (ALL) cell line, Reh . Specifically, we focused on the in vitro response to fludarabine, a chemotherapeutic agent used prior to allogenic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy in high-risk, refractory, or relapsed ALL patients. Using MPX, we quantified changes in protein abundance, spatial distribution, and colocalization of 76 targeted cell surface proteins in Reh cells before and after fludarabine treatment. Our analysis revealed 25 proteins with altered abundance, 24 proteins with increased polarity, and 138 protein pairs with modified colocalization following treatment. Notably, the tetraspanins CD82 and CD53, which are known for their roles in chemotherapy resistance, exhibited increased abundance, polarization, and colocalization post-treatment, suggesting their potential as a therapeutic scaffold. These findings underscore the unique ability of spatially resolved single-cell proteomics to uncover nuanced cellular responses that would otherwise remain undetected.